Wondering is reta or tirz better for weight loss? Retatrutide beats tirzepatide in early trials, but only tirzepatide is FDA-approved — here's how they compare.
There is no head-to-head clinical trial comparing retatrutide (reta) with tirzepatide (tirz), so no one can say for certain which one is better for weight loss. In separate trials, retatrutide has produced slightly larger average weight loss — roughly 24% of body weight at 48 weeks on the highest dose — while tirzepatide produced about 21% at 72 weeks. The bigger practical difference today is access: tirzepatide is FDA-approved and widely prescribed, and retatrutide is an investigational drug available only through clinical trials.
What Are Reta and Tirz?
Reta is short for retatrutide, an experimental drug developed by Eli Lilly. It is a triple agonist, meaning it activates three hormone receptors at once: GIP, GLP-1, and glucagon. The glucagon component is what makes retatrutide unusual — it appears to raise energy expenditure in addition to reducing appetite.
Tirz is short for tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It is a dual agonist that targets GIP and GLP-1 but not glucagon. It has been FDA-approved since 2022 for diabetes and since 2023 for weight loss.
The practical difference between reta and Mounjaro comes down to that third receptor. Adding glucagon activity may burn more calories, but it can also raise resting heart rate and cause a tingling skin sensation called dysesthesia that has not been reported with tirzepatide.
How Much Weight Loss Does Each Drug Produce?
Both drugs have produced some of the largest average weight losses ever recorded in obesity trials. The figures below come from separate studies with different designs, so they are not directly comparable.
| Drug | Mechanism | Approval status | Highest reported average weight loss |
|---|---|---|---|
| Retatrutide (reta) | Triple GIP/GLP-1/glucagon agonist | Investigational; Phase 3 trials ongoing | About 24% at 48 weeks (12 mg) |
| Tirzepatide (tirz) | Dual GIP/GLP-1 agonist | FDA-approved (Zepbound, Mounjaro) | About 21% at 72 weeks (15 mg) |
| Semaglutide (Wegovy) | GLP-1 agonist | FDA-approved | About 15% at 68 weeks (2.4 mg) |
If you are weighing tirzepatide vs semaglutide which is better for weight loss, tirzepatide also won that direct comparison in the SURMOUNT-5 trial, with 20.2% versus 13.7% weight loss at 72 weeks.
Retatrutide has not yet been compared directly with tirzepatide in a randomized trial. Phase 3 results from the TRIUMPH program are expected to clarify how the two drugs stack up.
Why Cross-Trial Comparisons Are Misleading
Reading two trial results side by side feels intuitive, but it can overstate the real difference between drugs. Trial duration, dose escalation, participant characteristics, and how weight loss is measured all vary.
- The retatrutide Phase 2 trial lasted 48 weeks, while the tirzepatide SURMOUNT-1 trial ran 72 weeks. Weight loss often keeps growing over time.
- Retatrutide's 24% figure came from a mid-stage study, and Phase 2 results sometimes look more impressive than Phase 3 results.
- Trial populations differ in baseline BMI, age, and whether participants have type 2 diabetes, which affects how much weight they lose.
That is why researchers generally avoid declaring a winner based on cross-trial numbers. Much of the reta vs mounjaro Reddit discussion leans on individual experiences, which are useful for understanding side effects but cannot establish which drug works better on average. No head-to-head clinical trial has compared retatrutide with tirzepatide for weight loss.
Side Effects and Safety
Both drugs are associated with gastrointestinal side effects, especially during dose escalation. Nausea, vomiting, diarrhea, and constipation are the most common complaints for each.
Retatrutide has shown a few signals that tirzepatide has not:
- Higher rates of nausea and vomiting at the highest doses
- Dysesthesia, a tingling or altered skin sensation, reported in a minority of participants
- Dose-dependent increases in resting heart rate
If your main question is is tirz safe for weight loss, the answer is that its risks are well documented and generally manageable under medical supervision. Common side effects are digestive, and serious complications such as pancreatitis or gallbladder disease are rare.
Retatrutide's safety profile is still being characterized. Because it is investigational, long-term data on thyroid, pancreatic, and cardiovascular outcomes do not yet exist.
Access, Cost, and Legal Status
Tirzepatide is available by prescription at most pharmacies, and insurance coverage varies widely. Compounded versions were sold during shortages, though the FDA has moved to restrict that practice as brand-name supply has stabilized.
Retatrutide is not FDA-approved for human use in the United States. It can be obtained only by enrolling in a clinical trial, and any "reta" sold online as a research chemical is unregulated, unverified, and potentially unsafe.
Over-the-counter peptide supplements for weight loss are not the same category of product at all. They are not GLP-1 or GIP receptor agonists, and they have not been shown to produce the weight loss seen with prescription incretin drugs.
What This Means If You Are Choosing a Medication
For most people seeking treatment right now, tirzepatide is the realistic option. It is approved, dosed in a well-studied range, and supported by years of clinical data.
Dose titration matters for any GLP-1 or dual agonist. The starting dose of semaglutide for weight loss is deliberately low, and the same slow ramp-up applies to tirzepatide, because jumping to an effective dose too quickly causes more side effects.
It also explains why increase dose of semaglutide for weight loss is such a common question as treatment continues. Appetite suppression often plateaus, so clinicians raise the dose step by step until the response is adequate or side effects become limiting.
Retatrutide is worth watching, but it is not yet a substitute for approved therapy. Anyone considering a clinical trial should discuss eligibility, risks, and alternatives with a healthcare professional.
Bottom Line
Retatrutide has produced slightly larger average weight loss than tirzepatide in separate trials, but no head-to-head study exists. Tirzepatide is FDA-approved for weight loss and available now, while retatrutide is still experimental. Neither drug is a cure, and both require medical supervision, lifestyle changes, and realistic expectations about results.
Frequently Asked Questions
Which is better for weight loss, retatrutide or tirzepatide?
No head-to-head trial has compared them, so there is no definitive answer. Retatrutide produced about 24% average weight loss at 48 weeks in a Phase 2 trial, while tirzepatide produced about 21% at 72 weeks in SURMOUNT-1. Tirzepatide is FDA-approved and available now, and retatrutide is still investigational.
Can you get retatrutide with a prescription in the United States?
No. Retatrutide is not FDA-approved for any use, so it cannot be legally prescribed by a US clinician. The only legitimate way to access it is by enrolling in one of the ongoing Phase 3 clinical trials. Products sold online as retatrutide are unregulated research chemicals and should be avoided.
Is tirzepatide safe for weight loss?
Tirzepatide is FDA-approved for chronic weight management, and its safety profile is well studied. The most common side effects are nausea, vomiting, diarrhea, and constipation, which usually ease after dose escalation. Serious complications such as pancreatitis and gallbladder disease are uncommon but possible, so treatment should be supervised by a healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.